Metabolic/Proteomic Signature Defines Two Glioblastoma Subtypes With Different Clinical Outcome.
about
Contribution of the Microenvironmental Niche to Glioblastoma Heterogeneity.CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells.Cancer stem cells from human glioblastoma resemble but do not mimic original tumors after in vitro passaging in serum-free media.Expression of Iron-Related Proteins Differentiate Non-Cancerous and Cancerous Breast Tumors.Proteomic analysis of cerebrospinal fluid from children with central nervous system tumors identifies candidate proteins relating to tumor metastatic spread.RYK promotes the stemness of glioblastoma cells via the WNT/ β-catenin pathwayIncorporating prior information into differential network analysis using non-paranormal graphical models.A three-microRNA signature identifies two subtypes of glioblastoma patients with different clinical outcomes.Emerging power of proteomics for delineation of intrinsic tumor subtypes and resistance mechanisms to anti-cancer therapies.The integrative metabolomic-transcriptomic landscape of glioblastome multiforme.PATZ1 is a new prognostic marker of glioblastoma associated with the stem-like phenotype and enriched in the proneural subtype.Interest of integrins targeting in glioblastoma according to tumor heterogeneity and cancer stem cell paradigm: an update.Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme.Metabolic Heterogeneity Evidenced by MRS among Patient-Derived Glioblastoma Multiforme Stem-Like Cells Accounts for Cell Clustering and Different Responses to Drugs.The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response.Developments in Blood-Brain Barrier Penetrance and Drug Repurposing for Improved Treatment of Glioblastoma
P2860
Q33786677-84BF6646-63A8-42EB-896E-EF469DFC9D57Q36340540-255040BE-944B-415E-91E7-7DF93742B72AQ37662331-AA0BDCDA-E00B-449F-A6B3-C390224D33EAQ37690976-76A34350-0EBC-41CD-8C9A-F3E297ED3C58Q38702839-C7C20411-54A2-4683-A92E-AB4E4374CC7AQ38721422-43D9C3AE-9D43-4A02-852C-D0651A1C3D14Q38838330-679CA983-FF5D-4C7D-9046-21FE8FEDFEECQ38935921-56DB64A0-9DA0-4323-9492-8FA180C0B1C6Q38947310-589B2D2F-5139-4B6B-8221-C1D43150CB21Q41472371-FF85E968-7786-4EEF-9E76-F7695092DF22Q41708852-4ECC5C6D-A138-4D48-8E1A-13B7D5C5E1A1Q44411444-260D2DEF-D816-4DB2-9BCD-880A57B1C23CQ45074720-DC612DA2-6CBA-4D63-8BBF-CBD39BE9F687Q52659354-3D534878-095B-4094-8061-543CE142515FQ53750643-0F5E6484-78E0-4E0B-BF86-2B81FB9D00B6Q58573420-609A6347-CF56-4D07-A214-3087819D853A
P2860
Metabolic/Proteomic Signature Defines Two Glioblastoma Subtypes With Different Clinical Outcome.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Metabolic/Proteomic Signature ...... th Different Clinical Outcome.
@ast
Metabolic/Proteomic Signature ...... th Different Clinical Outcome.
@en
type
label
Metabolic/Proteomic Signature ...... th Different Clinical Outcome.
@ast
Metabolic/Proteomic Signature ...... th Different Clinical Outcome.
@en
prefLabel
Metabolic/Proteomic Signature ...... th Different Clinical Outcome.
@ast
Metabolic/Proteomic Signature ...... th Different Clinical Outcome.
@en
P2860
P50
P356
P1433
P1476
Metabolic/Proteomic Signature ...... ith Different Clinical Outcome
@en
P2093
R De Maria
P2860
P2888
P356
10.1038/SREP21557
P407
P50
P577
2016-02-09T00:00:00Z